Introduction
============

Prostate cancer (PCa) is one of the most prevalent malignancy in male gender at developed country. There are estimated 174650 newly diagnosed cases and 31620 cancer-related death in the United States alone in 2019 [@B1]. The incidence of PCa increases with advancing age. And 64% of new diagnosed cases were older than age 65 years [@B2]. Consider the relative limited life expectancy; the older patients are more likely to receive active surveillance and observation, instead of potentially curative local therapy. However, the older patients were reported to get high-risk prostate cancer at diagnosis more frequently [@B3]. And age is also known as a risk factor of pathological upgrading to higher risk disease after radical prostatectomy [@B4]. The older men with high-risk disease, treated local therapy, had a 46 % reduction of mortality risk comparing with who treated conservatively [@B3]. In current practice, the older PCa patients often received insufficient diagnostic survey and subsequent curative treatment [@B5]. In order to balance between cancer specific mortality and overtreatment of these older patients, further prognostic factors to identify who needed aggressive cancer treatment is an important issue.

In the past, the screening of prostate cancer was based on elevated prostate specific antigen (PSA) and digital examination. And we classified risk of PCa progression combining with tumor stage, PSA and Gleason score of tumor grading. However, there are numerous newly published evidences indicated the importance of genetic features (both genomic alteration and single nucleotide polymorphism) in PCa prediction and prognosis [@B6]-[@B9].

Recently, studies about tumor biology started focusing not only the coding sequence but also evaluating the impact of long noncoding RNAs (LncRNAs). LncRNAs defined as longer than 200 nucleotides and do not have ability to translate [@B10]. Although not in charge of protein coding, the LncRNAs can have regulatory effects of cell differentiation, migration, proliferation and apoptosis by interacting with DNA, RNA and proteins [@B11]-[@B13]. And genetic variant over the promoter region of LncRNA was reported to modulate the expression level by methylation [@B14].

Growth arrest-specific 5 (GAS5), a LncRNA encoded by the GAS5 gene, is recently identified as a tumor suppressor in several cancers such as lung, breast, prostate and colorectal cancers [@B15]. Although the exact expression level of GAS5 in PCa cell is still controversy, GAS5 is thought to play an important role in the proliferation, invasion, migration, and metastasis of PCa cells [@B16]-[@B18]. The expression of GAS5 was identified to downregulate microRNA-21(miR-21)/miR-1284, then increase the expression PTEN/ PCDC4/AKT and result in cell apoptosis and limit proliferation of prostate cancer cell [@B19].

Single nucleotide polymorphism (SNP) is defined as a single nucleotide from the shared genome sequence changed more than 1% within a population [@B20]. Several genetic polymorphisms had been associated with PCa risk, tumor grading and PCa specific mortality [@B21]-[@B23]. The variant rs145204276, shown as "-/AGGCA ", is a 5-bp indel polymorphism in the GAS5 promoter region. Rs145204276 was reported to affect expression of GAS5 and increase susceptibility of several cancers [@B24]-[@B26]. Moreover, this SNPs of GAS5 gene was reported significantly affecting the gleason score, disease stage and prognosis of prostate cancer [@B19]. But, there are only 158 PCa patients included in this study, and this sample size is a little below power to conclude the susceptibility of prostate cancer and SNP of GAS5. Our study design is to further test the effect of SNP rs145204276 of GAS5 in PCa patient. To our knowledge, this study has the biggest sample size to test correlation of the SNP of GAS5 and cancer susceptibility and clinicopathologic characteristics of PCa patients in Taiwan to date.

Materials and Methods
=====================

Description of enrolled subjects
--------------------------------

In this study, we enrolled 579 patients with adenocarcinoma of prostate, underwent robotic assisted radical prostatectomy from 2012 to 2017 at Taichung Veteran General Hospital. At the same time, 579 age-matched individuals were also included as healthy control. Before opening of this study, the approval was certified by the Institutional Review Broad (IRB) of Taichung Veteran General Hospital, and the informed consent was written by each participant (IRB No. CE19062A). The medical information for each patient was acquired from personal medical records, including initial PSA level at diagnosis, Gleason score of initial biopsy, clinical and pathological TNM staging, Gleason grade group [@B27], D\'Amico classification [@B28] and all the pathological features of permanent pathological result.

Specimen collection and Genomic DNA extraction
----------------------------------------------

Whole blood samples were collected from controls and PCa patients. There were 579 PCa patients included and all the blood sample were obtained before surgery. The specimens were placed in tubes with EDTA, centrifuged immediately then stored at -80 ^o^C. Genomic DNA was extracted from whole blood sample with QIAamp DNA blood mini kits (Qiagen, Valencia, CA, USA) based on the manufacture\'s instruction as described previously [@B29]. DNA was dissolved with TE buffer and stored at -20°C before Real-time PCR analysis.

Selection of GAS5 genetic polymorphism
--------------------------------------

The GAS5 variant rs145204276 is a 5-bp indel polymorphism located at the promoter region. Rs145204276 was selected in this study since this SNP was associated with the progression of several cancers [@B24]-[@B26]. The SNP rs145204276 of GAS5 was genotyped with TaqMan assay with SDS 3.0 software (Applied Biosystems, Foster City, CA, USA) and interpreted with StepOne™ Real-time PCR (RT-PCR) System (Applied Biosystems, Foster City, CA, USA).

Statistical analysis
--------------------

A goodness-of-fit v2 test was used to exam Hardy-Weinberg equilibrium for biallelic markers. Mann-Whitney U test were used to evaluate the differences among demographic characteristics between PCa group and controls. The odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using logistic regression models to estimate the association between genotypic frequencies and different clinicopathological characteristics. The statistical significant difference was defined as p\<0.05. All the data were analyzed using Statistical Analytic System (SAS Institute, Cary, NC, USA) software (vers. 9.1, 2005) for Windows.

Results
=======

Characteristics of Study Participants
-------------------------------------

The demographic characteristics in 579 patients were presented in this study (Table [1](#T1){ref-type="table"}). At diagnosis, 334 patients (57.7%) were older than 65-year-old, 270 patients (46.6%) had initial PSA level more than 10 ng/mL, 501 patients (86.5%) were clinically localized disease (cT1+cT2). 273 and 49 patients had pathological proof locally advanced disease (pT3+pT4) (47.2%) and lymph node metastasis (8.5%) respectively. The percentages of low-, intermediate-, and high-risk PCa according to D\'Amico classification were 10.4% (60), 38.0% (220), and 51.6% (299).

Association of GAS5 gene polymorphisms and cancer susceptibility and clinical status of PCa
-------------------------------------------------------------------------------------------

The allele frequency of GAS5 rs145204276 SNP in the patients with PCa and non-cancer controls is shown in Table [2](#T2){ref-type="table"}. In our recruited control group, the frequencies of GAS5 rs145204276 (χ^2^ value: 0.132, p=0.717) was in Hardy-Weinberg equilibrium. However, there are no significant correlations noted in all codominant/dominant/recessive/additive models. In the table [3](#T3){ref-type="table"}, we evaluate the association of clinicopathologic characteristics of patients with PCa and GAS5 rs145204276 polymorphism. Patients who carries genotype ins/del or del/del showed decreased risk of pathological lymph node metastasis disease (OR=0.545; 95% CI=0.301-0.988, p=0.043) and risk of seminal vesicle invasion (OR=0.632; 95% CI=0.426-0.939, p=0.022) comparing to with genotype ins/ins. The risk of lymphovascular invasion is also slightly lower in patients who carry at least one del phenotype but there is no statistical significance (OR=0.647; 95% CI=0.435-1.044, p=0.076). And no difference was noted in other well-known prognostic factors such as initial PSA level, pathological gleason grade group, clinical/pathological T stage and D\'Amico risk classification.

Correlation of GAS5 SNPs and clinical status of PCa with age over 65 years
--------------------------------------------------------------------------

In the table [4](#T4){ref-type="table"}, we evaluate the association of GAS5 rs145204276 polymorphism and clinicopathologic characteristics of patients with PCa and older than 65 years. Patients who carries GAS5 rs145204276 ins/del or del/del showed decreased risk of clinical locally advanced disease (OR=0.513; 95% CI=0.286-0.923, p=0.024), pathological lymph node metastasis disease (OR=0.462; 95% CI=0.225-0.946, p=0.032) and lymphovascular invasion (OR=0.521; 95% CI=0.292-0.927, p=0.025) comparing to with genotype ins/ins. The risk of higher initial PSA level (\> 10 ng/mL) and seminal vesicle invasion are also slightly lower in patients who carry at least one del phenotype but there is no statistical significance (OR=0.676; 95% CI=0.435-1.049, p=0.080; and OR=0.613; 95% CI=0.370-1.018, p=0.057, respectively). And no difference was noted in other well-known prognostic factors such as pathological gleason grade group, pathological T stage and D\'Amico risk classification.

Discussion
==========

Recently, increasing evidence indicated that decreasing expression of GAS5 can affect the susceptibility of many kinds of cancers and associated with poorer prognosis of hepatocellular carcinoma, cervical cancer, renal cancer, lung cancer, gastric cancer and melanoma [@B24]-[@B26], [@B30]-[@B32]. The rs145204276 ins/del polymorphism can regulate the expression of GAS5 through affecting one CpG island methylation condition [@B24]. Cancer patients with allele del of rs145204276 were also found to have remarkable higher expression of GAS5 in several different cancer tissues, and prostate cancer is one of them [@B19], [@B24]-[@B26], [@B33]. The del allele of rs145204276 was also significantly correlated with decrease risk of lung cancer, hepatocellular carcinoma and gastric cancer [@B24]-[@B26]. However, in our study, the del allele of rs145204276 did not affect the tumor susceptibility of prostate cancer. The result did not change when evaluating with codominant, dominant, recessive or additive model. The reason might be the risk of prostate cancer had already connected with numerous SNPs [@B34], [@B35]. Thus, the effect of GAS5 SNP about prostate cancer susceptibility became attenuated. To the best of our knowledge, this is the first study to evaluate the genetic polymorphism of GAS5 with susceptibility of prostate cancer.

In the analysis about clinicopathologic characteristics of prostate cancer in whole population, SNP rs145204276 was significantly associated with decreasing risk of pathological proved lymph node metastasis (OR=0.545; 95% CI=0.301-0.988, p=0.043) and risk of seminal vesicle invasion (OR=0.632; 95% CI=0.426-0.939, p=0.022). There was also a better trend of decreasing lymphovascular invasion (OR=0.647; 95% CI=0.435-1.044, p=0.076). Lymphovascular invasion, also known as minimal lymphatic involvement, has been frequently reported as a prognostic factor to predict biochemical recurrence (BCR) after radiotherapy and radical prostatectomy [@B36]-[@B39]. In the cause analysis of BCR, the increasing risk was mainly from progression to lymph node metastasis instead of residual tumor cells of positive surgical margins [@B39]. A recent study reported that the lymphovascular invasion of PCa cells has a significantly prognostic impact on disease progression.[@B40]

Although we cannot provide the direct impact of SNP rs145204276 and the survival outcome, but considering the presence of lymph node metastasis after radical prostatectomy is a well-known poor prognostic factor with increased long-term risk of cancer specific mortality, estimated to range from 20% to 42% [@B41]-[@B43]. A worse cancer specific survival in patient with SNP rs145204276 might be a reasonable expectation, but further direct evidence to validate is still needed.

In the subgroup analysis of PCa patients with age classification, we realized the risk reduction effect of lymph node metastasis in patients with SNP rs145204276 is mainly contributed by the elders. PCa patients with age more than 65 year and carrying SNP rs145204276 are correlated to a 57.4% risk reduction of pathological proved lymph node metastasis (OR=0.426; 95% CI=0.225-0.946, p=0.032) and 47.9% risk reduction of lymphovascular invasion (OR=0.521; 95% CI=0.292-0.927, p=0.025) significantly. And these risk reduction effects were not revealed in the age below or equal to 65 years\' population.

In the current real world practice of PCa treatment, the older patients are more likely to receive active surveillance and observation, instead of potentially curative local therapy because of the relative limited life expectancy. However, the older patients were reported to have more aggressive prostate cancer at diagnosis more frequently [@B3]. And age is also considered as a risk factor of pathological upgrading to higher risk disease after operation[@B4]. In older men with high-risk disease, the aggressive treatment with a 46 % reduction of mortality risk was reported comparing to treat conservatively [@B3]. To balance between survival benefit and overtreatment of these older patients, further prognostic factors to initiate or avoid aggressive cancer treatment is an important issue. And GAS5 SNP rs145204276 could be part of the resolution. In our study, GAS5 SNP rs145204276 showed a strong prevention effect of lymphatic spreading in PCa patient older than 65 years. In the future study, the precise genetic mechanism with multifactorial evaluation of prostate cancer pathogenesis and prognosis is worthy for investigation.

In conclusion, although the GAS5 SNP rs145204276 did not affect the PCa susceptibility, our study indicated men with PCa and carrying GAS5 SNP rs145204276 are less likely to develop lymph node metastasis, especially in the age older than 65 years\' group.

###### 

The distributions of demographical characteristics in 579 patients with prostate cancer.

  Variable                             Patients (N=579)
  ------------------------------------ ------------------
  **Age at diagnosis (years)**         
  ≤ 65                                 245 (42.3 %)
  \> 65                                334 (57.7 %)
  **PSA at diagnosis (ng/mL)**         
  ≤ 10                                 309 (53.4 %)
  \> 10                                270 (46.6 %)
  **Pathologic Gleason grade group**   
  1+2+3                                484 (83.6 %)
  4+5                                  95 (16.4 %)
  **Clinical T stage**                 
  1+2                                  501 (86.5 %)
  3+4                                  78 (13.5 %)
  **Pathologic T stage**               
  2                                    306 (52.8 %)
  3+4                                  273 (47.2 %)
  **Pathologic N stage**               
  N0                                   530 (91.5 %)
  N1                                   49 (8.5 %)
  **Seminal vesicle invasion**         
  No                                   452 (78.1 %)
  Yes                                  127 (21.9 %)
  **Perineural invasion**              
  No                                   155 (26.8 %)
  Yes                                  424 (73.2 %)
  **Lymphovascular invasion**          
  No                                   482 (83.2 %)
  Yes                                  97 (16.8 %)
  **D\'Amico classification**          
  Low risk                             60 (10.4 %)
  Intermediate risk                    220 (38.0 %)
  High risk                            299 (51.6 %)

###### 

Associations between GAS5 rs145204276 and 579 patients with prostate cancer.

  Genetic model          Genotype            Controls (N=579) n (%)   Patients (N=579) n (%)   OR (95% CI)           p value
  ---------------------- ------------------- ------------------------ ------------------------ --------------------- ---------
  **Codominant model**   Ins/Ins             237 (40.9%)              263 (45.4%)              1.000                 
                         Ins/Del             270 (46.7%)              252 (43.5%)              0.841 (0.658-1.075)   p=0.167
                         Del/Del             72 (12.4%)               64 (11.1%)               0.801 (0.548-1.171)   p=0.252
  **Dominant model**     Ins/Ins             237 (40.9%)              263 (45.4%)              1.000                 
                         Ins/Del + Del/Del   342 (59.1%)              316 (54.6%)              0.833 (0.660-1.051)   p=0.123
  **Recessive model**    Ins/Ins + Ins/Del   507 (87.6%)              515 (88.9%)              1.000                 
                         Del/Del             72 (12.4%)               64 (11.1%)               0.875 (0.612-1.252)   p=0.465
  **Additive model**     Ins allele          744 (64.2%)              778 (67.2%)              1.000                 
                         Del allele          414 (35.8%)              380 (32.8%)              0.878 (0.739-1.042)   p=0.137

The odds ratios (ORs) and with their 95% confidence intervals (CIs) were estimated by logistic regression models.

###### 

Odds ratio (OR) and 95% confidence interval (CI) of clinical status and *GAS5* rs145204276 genotypic frequencies in 579 patients with prostate cancer.

  ------------------------------------------------------------------------------------------------------------
  Variable                             Genotypic frequencies                                       
  ------------------------------------ ----------------------- ------------- --------------------- -----------
  **PSA at diagnosis (ng/mL)**                                                                     

  ≤ 10                                 148 (56.3%)             161 (50.9%)   1.00                  p=0.201

  \> 10                                115 (43.7%)             155 (49.1%)   1.239 (0.892-1.721)   

  **Pathologic Gleason grade group**                                                               

  1+2+3                                216 (82.1%)             268 (84.8%)   1.00                  p=0.386

  4+5                                  47 (17.9%)              48 (15.2%)    0.823 (0.530-1.278)   

  **Clinical T stage**                                                                             

  1+2                                  223 (84.8%)             278 (88.0%)   1.00                  p=0.264

  3+4                                  40 (15.2%)              38 (12.0%)    0.762 (0.473-1.229)   

  **Pathologic T stage**                                                                           

  2                                    140 (53.2%)             166 (52.5%)   1.00                  p=0.867

  3+4                                  123 (46.8%)             150 (47.5%)   1.029 (0.741-1.427)   

  **Pathologic N stage**                                                                           

  N0                                   234 (89.0%)             296 (93.7%)   1.00                  p=0.043\*

  N1                                   29 (11.0%)              20 (6.3%)     0.545 (0.301-0.988)   

  **Seminal vesicle invasion**                                                                     

  No                                   194 (73.8%)             258 (81.6%)   1.00                  p=0.022\*

  Yes                                  69 (26.2%)              58 (18.4%)    0.632 (0.426-0.939)   

  **Perineural invasion**                                                                          

  No                                   63 (24.0%)              92 (29.1%)    1.00                  p=0.163

  Yes                                  200 (76.0%)             224 (70.9%)   0.767 (0.528-1.114)   

  **Lymphovascular invasion**                                                                      

  No                                   211 (80.2%)             271 (85.8%)   1.00                  p=0.076

  Yes                                  52 (19.8%)              45 (14.2%)    0.674 (0.435-1.044)   

  **D\'Amico classification**                                                                      

  Low risk/\                           129 (49.0%)             151 (47.8%)   1.00                  p=0.762
  Intermediate risk                                                                                

  High risk                            134 (51.0%)             165 (52.2%)   1.052 (0.758-1.459)   
  ------------------------------------------------------------------------------------------------------------

The ORs with analyzed by their 95% CIs were estimated by logistic regression models. \* p value \< 0.05 as statistically significant.

###### 

Odds ratio (OR) and 95% confidence interval (CI) of clinical status and *GAS5* rs145204276 genotypic frequencies in 334 prostate cancer patients with age over 65 years.

  ------------------------------------------------------------------------------------------------------------
  Variable                             Genotypic frequencies                                       
  ------------------------------------ ----------------------- ------------- --------------------- -----------
  **PSA at diagnosis (ng/mL)**                                                                     

  ≤ 10                                 57 (36.3%)              81 (45.8%)    1.00                  p=0.080

  \> 10                                100 (63.7%)             96 (54.2%)    0.676 (0.435-1.049)   

  **Pathologic Gleason grade group**                                                               

  1+2+3                                122 (77.7%)             146 (82.5%)   1.00                  p=0.274

  4+5                                  35 (22.3%)              31 (17.5%)    0.740 (0.431-1.270)   

  **Clinical T stage**                                                                             

  1+2                                  123 (78.3%)             155 (87.6%)   1.00                  p=0.024\*

  3+4                                  34 (21.7%)              22 (12.4%)    0.513 (0.286-0.923)   

  **Pathologic T stage**                                                                           

  2                                    78 (49.7%)              91 (51.4%)    1.00                  p=0.752

  3+4                                  79 (50.3%)              86 (48.6%)    0.933 (0.607-1.434)   

  **Pathologic N stage**                                                                           

  N0                                   134 (85.4%)             164 (92.7%)   1.00                  p=0.032\*

  N1                                   23 (14.6%)              13 (7.3%)     0.462 (0.225-0.946)   

  **Seminal vesicle invasion**                                                                     

  No                                   112 (71.3%)             142 (80.2%)   1.00                  p=0.057

  Yes                                  45 (28.7%)              35 (19.8%)    0.613 (0.370-1.018)   

  **Perineural invasion**                                                                          

  No                                   33 (21.0%)              50 (28.2%)    1.00                  p=0.127

  Yes                                  124 (79.0%)             127 (71.8%)   0.676 (0.408-1.119)   

  **Lymphovascular invasion**                                                                      

  No                                   122 (77.7%)             154 (87.0%)   1.00                  p=0.025\*

  Yes                                  35 (22.3%)              23 (13.0%)    0.521 (0.292-0.927)   

  **D\'Amico classification**                                                                      

  Low risk/\                           62 (39.5%)              77 (43.5%)    1.00                  p=0.458
  Intermediate risk                                                                                

  High risk                            95 (60.5%)              100 (56.5%)   0.848 (0.548-1.312)   
  ------------------------------------------------------------------------------------------------------------

The ORs with analyzed by their 95% CIs were estimated by logistic regression models. \* p value \< 0.05 as statistically significant.
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